Human Immunodeficiency Virus Type 1 (HIV 1) Market Growth, Analysis and Forecast 2023 to 2033Posted by Ganesh Shinde on February 23rd, 2023 The global human immunodeficiency virus type 1 (HIV 1) market is predicted to exceed a remarkable valuation of US$ 34.83 Billion in 2023, with a compound annual rate of growth (CAGR) of 6% estimated from 2023 to 2033. The Institute for Health Metrics and Evaluation attributes the industry's growth to the soaring incidence rate of HIV-1 infection, which, unlike the deaths caused from this viral illness, has not updated substantially over time. It affected approximately 37 million people worldwide. Furthermore, antiretroviral therapeutic interventions for disease management are only available to half of this population. HIV-1 is the more common of the two types of human immunodeficiency virus, accounting for approximately 96% of all infections globally. The prevalence of HIV is rising at an alarming rate. The World Health Organization (WHO) estimates that 33.0 million individuals are infected with HIV. This has heightened public awareness, which is directing to an increase in testing procedures. This will cause an increase in demand for HIV medicines with greater efficacy for treatment and care over the projected period. Because of the large percentage of HIV patients in highly populous countries such as China and India, the Asia Pacific market is expected to become the fastest-growing market with the highest CAGR over the coming years. Furthermore, the massive amount of therapeutic interventions, as well as monetary support from corporate companies and medical companies, are anticipated to propel the industry forward. Key Market Players Key players in the Human Immunodeficiency Virus Type 1 (HIV 1) market areAbbVie, Inc., Boehringer, Ingelheim GmbH. Bristol-Myers Squibb Company, Cipla, Inc, Genentech, Inc, Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare, GlaxoSmithKline, Sanofi. Know More Details About Report@ https://www.futuremarketinsights.com/reports/human-immunodeficiency-virus-type-1-hiv1-market Key Segments Profiled in the Human Immunodeficiency Virus Type 1 (HIV 1) Market Industry Survey Human Immunodeficiency Virus Type 1 (HIV 1) Market by Drug Class:
Like it? Share it!More by this author |